Site Search

1. 121.
   AMP/assets/File/awards/young_investigator/YIA_WinningAbstracts_2016.pdf?pass=29

   In 20/37 (54.1%) PT samples, MRD was detected by CE and/ ... MRD in 19/20 of these cases (sensitivity=95%). LT did not detect MRD in a case of PCN, but FC detected 0.0028% plasma cells suspicious for disease. In 8/37 (21.6%) PT samples, only LT detected MRD, whereas FC and ... failed to detect any disease. In 11/37 (29.7%) PT samples, both LT and FC detected MRD, whereas

   https://www.amp.org/AMP/assets/File/awards/young_investigator/YIA_WinningAbstrac...
2. 122.
   AMP/assets/File/education/case-studies/1118_14-16_AMPcase-Reprint_LR.pdf?pass=15

   Genetic mutations (VAF %) KRAS G12C (22%) TP53 T18Hfs*26 (23%) NRAS G12D (15%) KRAS G12D (3%) No data KRAS G12C (38%) TP53 T18Hfs*26 (41%) NRAS G12D (3%) KRAS G12D (6%) No data ——NRAS G12D (34%) KRAS G12D (3%) ASXL1 Q760* (43%) and are less likely to be ... characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting

   https://www.amp.org/AMP/assets/File/education/case-studies/1118_14-16_AMPcase-Re...
3. 123.
   AMP/assets/File/annualreports/AMPAnnualReport2014-FINAL.pdf?pass=9

   Doctoral Scientists 5% Trainees Technologists Others Interested in Advancing ... and fellows, by more than 30%. We’re thrilled to be home ... Medical Centers AMP members work in: 19% 8% 4% 10%14% 38% Public Policy 2014 was a busy year ... Heath IT Incidental Findings Doctoral Scientists 10% 3% 39% 13% 35% Trainees Technologists Others Interested in Advancing AMP

   https://www.amp.org/AMP/assets/File/annualreports/AMPAnnualReport2014-FINAL.pdf?...
4. 124.
   AMP/assets/File/advocacy/AMP-Response-GAO-report-re-FDA-policy-response.pdf?pass...

   You can find the full findings from these surveys here: https://www.amp.org/advocacy/sars-cov-2-survey/Our analysis ... process in an attempt to mitigate testing delays, approximately 35% of the laboratory professionals surveyed (both AMP members and non ... could have easily been answered up front. In fact, 32% of the respondents in one of our 2020 surveys said

   https://www.amp.org/AMP/assets/File/advocacy/AMP-Response-GAO-report-re-FDA-poli...
5. 125.
   AMPflicationsAugust2015

   Director, contact information may be found at: https://www.cms.gov/medicare-coverage-database/indexes/contacts-part-b-medicare-administrativecontractor-index.aspx?bc= ... in diagnostic medicine. The paper is available here: http://jmd.amjpathol.org/article/S1525-1578%2815%2900071-9/abstract OPPORTUNITIES FOR YOU The deadline to apply to serve on the AMP

   https://www.amp.org/AMP/assets/File/newsletter/AMPflicationsAugust2015.pdf?pass=...
6. 126.
   AMP/assets/File/advocacy/AMPLetter-LABAct-10-16-2019-FINAL.pdf?pass=16

   CLFS, fifty-seven percent (57%) decreased in value from their 2017 National Limitation Amount ( ... Ninety (90) molecular tests decreased in value by thirty percent (30%) or more. 1 Protecting Access to Medicare Act of 2014, H ... on the CY2019 Medicare Physician Fee Schedule Proposed Rule. Accessed at https://www.amp.org/AMP/assets/AMP_Comments_PFSCY2019_CMS-1693-P

   https://www.amp.org/AMP/assets/File/advocacy/AMPLetter-LABAct-10-16-2019-FINAL.p...
7. 127.
   AMP/assets/File/pressreleases/2023/Press_Release_AMP_CYP3A4_CYP3A5.pdf?pass=13

   A (CYP3A) serves an important role in the metabolic transformation of approximately 50% of marketed drugs, including fentanyl, midazolam, quetiapine, ... activity, a prevalence of greater than 1% in at least one ancestral subpopulation, and ... care.” To read the full manuscript, please visit https://doi.org/10.1016/j.jmoldx.2023.06.008. ABOUT AMP

   https://www.amp.org/AMP/assets/File/pressreleases/2023/Press_Release_AMP_CYP3A4_...
8. 128.
   AMP/assets/File/advocacy/AMPLetter-LABAct-10-16-2019-FINAL.pdf?pass=14

   CLFS, fifty-seven percent (57%) decreased in value from their 2017 National Limitation Amount ( ... Ninety (90) molecular tests decreased in value by thirty percent (30%) or more. 1 Protecting Access to Medicare Act of 2014, H ... on the CY2019 Medicare Physician Fee Schedule Proposed Rule. Accessed at https://www.amp.org/AMP/assets/AMP_Comments_PFSCY2019_CMS-1693-P

   https://www.amp.org/AMP/assets/File/advocacy/AMPLetter-LABAct-10-16-2019-FINAL.p...
9. 129.
   AMP/assets/File/advocacy/AMPLetter-LABAct-10-16-2019-FINAL.pdf?pass=46

   CLFS, fifty-seven percent (57%) decreased in value from their 2017 National Limitation Amount ( ... Ninety (90) molecular tests decreased in value by thirty percent (30%) or more. 1 Protecting Access to Medicare Act of 2014, H ... on the CY2019 Medicare Physician Fee Schedule Proposed Rule. Accessed at https://www.amp.org/AMP/assets/AMP_Comments_PFSCY2019_CMS-1693-P

   https://www.amp.org/AMP/assets/File/advocacy/AMPLetter-LABAct-10-16-2019-FINAL.p...
10. 130.
    AMP/assets/File/advocacy/AMP Comments on CMS-OIG 12-31-2019.pdf?pass=10

    Act of 2014 (PAMA), reimbursement for clinical diagnostic laboratory tests is expected to be cut by as much as 30% by 2020 and potentially 45% by 2023.4 These cuts are especially damaging in the ... Services. Medicare clinical diagnostic laboratory tests payment system final rule. https://www.cms.gov/Newsroom/MediaReleaseDatabase/Fact-sheets/2016-Fact-sheets

    https://www.amp.org/AMP/assets/File/advocacy/AMP Comments on CMS-OIG 12-31-2019....